Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90048


Purpose:

The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.


Study summary:

As per brief summary


Criteria:

Inclusion Criteria: - Meet DSM-IV criteria for current major depression, and have a HAM-D (21 item) score of > 17 - Male or female who, if of child-bearing potential, agrees to use effective contraception including the regular use of contraceptive pills, intra-uterine devices, barrier methods or abstinence - Age between 18 and 65 - Capable of giving informed consent Exclusion Criteria: - Diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression or bipolar disorders - Current drug or alcohol abuse or dependence, or history of drug or alcohol abuse or dependence within the previous 6 months - Unstable medical or neurological conditions that are likely to interfere with the treatment of depression - History of allergy to citalopram or ProEPA, finfish or shellfish - History of failure of response to citalopram, as documented by an adequate trial of the medication [defined as having been treated with the medication at a dose level typically regarded as adequate (i.e., 40 mg of citalopram per day) for at least 6 weeks] - History of seizure disorder - Pregnancy - Currently on psychotropic medications including antidepressants or neuroleptics - Active suicidal ideation or other safety issues determined by the clinician to not be suitable for inclusion in the study - Exposure to treatment with fluoxetine or MAOIs in the previous two months - Patients on anticoagulant therapy - Patients with a dietary intake of > 3.0g total omega-3 PUFA/day at baseline


NCT ID:

NCT00067301


Primary Contact:

Principal Investigator
Lev Gertsik, MD
Cedars-Sinai Medical Center


Backup Contact:

N/A


Location Contact:

Los Angeles, California 90048
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.